Impact of hypertension and renin–angiotensin system inhibitors in aortic stenosis

Experimental studies revealed that renin–angiotensin system (RAS) could play a crucial role in the pathophysiology of aortic stenosis (AS). The objectives of this study were to examine (i) the impact of hypertension on AS progression and clinical events and (ii) the effect of angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin‐receptor blockers (ARBs).

[1]  G. Faggian,et al.  Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. , 2012, The Journal of thoracic and cardiovascular surgery.

[2]  P. Pibarot,et al.  Improving assessment of aortic stenosis. , 2012, Journal of the American College of Cardiology.

[3]  B. Gersh,et al.  Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. , 2012, European heart journal.

[4]  E. Staal,et al.  Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events , 2012, Hypertension.

[5]  J. Després,et al.  Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves , 2011, European journal of clinical investigation.

[6]  C. Lang,et al.  Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.

[7]  Jan-Hung Chen,et al.  &bgr;-Catenin Mediates Mechanically Regulated, Transforming Growth Factor-&bgr;1–Induced Myofibroblast Differentiation of Aortic Valve Interstitial Cells , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Després,et al.  Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. , 2010, International journal of cardiology.

[9]  R. Brooks,et al.  Evidence for Active Regulation of Pro-Osteogenic Signaling in Advanced Aortic Valve Disease , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[10]  L. Tarantini,et al.  Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis , 2010, Heart.

[11]  J. Daubert,et al.  Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay , 2010, Heart.

[12]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[13]  Y. Bossé,et al.  Refining Molecular Pathways Leading to Calcific Aortic Valve Stenosis by Studying Gene Expression Profile of Normal and Calcified Stenotic Human Aortic Valves , 2009, Circulation. Cardiovascular genetics.

[14]  P. Pibarot,et al.  Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. , 2009, Journal of the American College of Cardiology.

[15]  M. Beer,et al.  Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis , 2009, Circulation.

[16]  G. Cioffi,et al.  Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. , 2009, JACC. Cardiovascular imaging.

[17]  J. Després,et al.  Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease , 2009, Hypertension.

[18]  M. Borggrefe,et al.  Aortic valve calcification: basic science to clinical practice , 2008, Heart.

[19]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[20]  J. Després,et al.  Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[21]  A. Tajik,et al.  Timing of operation in asymptomatic severe aortic stenosis , 2007, Expert review of cardiovascular therapy.

[22]  P. Pibarot,et al.  Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis Despite Preserved Ejection Fraction Is Associated With Higher Afterload and Reduced Survival , 2007, Circulation.

[23]  R. Bonow,et al.  Calcific aortic stenosis: an update , 2007, Nature Clinical Practice Cardiovascular Medicine.

[24]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[25]  K. O’Brien.  Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  Damien Garcia,et al.  Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. , 2005, Journal of the American College of Cardiology.

[28]  Rosario V. Freeman,et al.  Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies , 2005, Circulation.

[29]  M. Budoff,et al.  Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. , 2005, Archives of internal medicine.

[30]  S. Hagl,et al.  Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[31]  M. Mäyränpää,et al.  Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.

[32]  M. Schemper,et al.  Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.

[33]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[34]  P. Faggiano,et al.  Symptomatic Aortic Stenosis: Does Systemic Hypertension Play an Additional Role? , 2003, Hypertension.

[35]  J. Schaper,et al.  Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.

[36]  J. Townend,et al.  ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? , 2001, Journal of Human Hypertension.

[37]  Bonnie K. Lind,et al.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. , 1997, Journal of the American College of Cardiology.

[38]  Catherine M. Otto,et al.  Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .

[39]  C. Otto,et al.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[40]  J. Laragh,et al.  Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. , 1995, Journal of the American College of Cardiology.

[41]  A. Gown,et al.  Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.

[42]  M. Rosenqvist,et al.  Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. , 1994, Journal of the American College of Cardiology.

[43]  W. Aronow,et al.  Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. , 1987, The American journal of cardiology.

[44]  Mark D. Huffman,et al.  Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[45]  C. Simmons,et al.  Mechanobiology of the aortic heart valve. , 2008, The Journal of heart valve disease.

[46]  G. Bondjers,et al.  Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. , 1997, Arteriosclerosis, thrombosis, and vascular biology.